The UBXN2A Antibody (PAC017563) is a polyclonal antibody designed for research involving UBXN2A, a protein involved in various cellular processes, including protein degradation and inflammation regulation. The antibody, produced in rabbits, is highly specific to human samples and is validated for use in Western blot and immunohistochemistry applications. It binds specifically to the UBXN2A protein, allowing for accurate detection and analysis in a variety of cell types, making it ideal for studies in cell biology and inflammation research.
UBXN2A is known for its role in protein quality control mechanisms, specifically in the regulation of protein turnover and degradation pathways. It also plays a part in modulating inflammatory responses, making it a potential target for research into diseases such as cancer, neurodegenerative disorders, and autoimmune conditions. Understanding the function of UBXN2A is crucial for advancing our knowledge of these diseases and developing targeted therapies to address them.
Antibody Name:
UBXN2A Antibody (PACO17563)
Antibody SKU:
PACO17563
Size:
50ul
Host Species:
Rabbit
Tested Applications:
ELISA, WB
Recommended Dilutions:
ELISA:1:1000-1:2000, WB:1:200-1:1000
Species Reactivity:
Human, Mouse
Immunogen:
Synthetic peptide of human UBXN2A
Form:
Liquid
Storage Buffer:
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Purification Method:
Antigen affinity purification
Clonality:
Polyclonal
Isotype:
IgG
Conjugate:
Non-conjugated
Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Mouse liver tissue, Primary antibody: PACO17563(UBXN2A Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds.
Background:
The protein is located in both the ER and cis-Golgi compartments from biochemical and immunofluorescence studies.UBXD4 as one of the cytosolic proteins that interact directly with the α 3 and α 4 nAChR subunits.Overexpression of UBXD4 in differentiated PC12 cells (dPC12) increased nAChR cell surface expression, especially that of the α 3 β 2 subtype.